Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

被引:2
|
作者
Liu, Tong [1 ]
Meng, Guorui [1 ]
Ma, Shihui [1 ]
You, Junqi [1 ]
Yu, Liang [1 ]
He, Risheng [1 ]
Zhao, Xudong [1 ]
Cui, Yunfu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; tumor immune microenvironment; review; OPEN-LABEL; INFUSION CHEMOTHERAPY; PLUS; MULTICENTER; BEVACIZUMAB; SINTILIMAB; LENVATINIB; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fimmu.2024.1455716
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset is insidious, and most patients have no obvious discomfort in the early stage, so it is found late, and the opportunity for surgical radical treatment is lost, resulting in a poor prognosis. With the introduction of molecular-targeted drugs represented by sorafenib, patients with middle- and late-stage liver cancer have regained the light of day. However, their therapeutic efficacy is relatively low due to the limited target of drug action, toxic side effects, and other reasons. At this time, the emergence of immunotherapy represented by immune checkpoint inhibitors (ICIs) well breaks this embarrassing situation, which mainly achieves the anti-tumor purpose by improving the tumor immune microenvironment. Currently, ICI monotherapy, as well as combination therapy, has been widely used in the clinic, further prolonging the survival of patients with advanced hepatocellular carcinoma. This article reviews the development of monotherapy and combination therapy for ICIs in advanced hepatocellular carcinoma and the latest research progress.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Longo, Vito
    Brunetti, Oronzo
    Gnoni, Antonio
    Licchetta, Antonella
    Delcuratolo, Sabina
    Memeo, Riccardo
    Solimando, Antonio Giovanni
    Argentiero, Antonella
    MEDICINA-LITHUANIA, 2019, 55 (10):
  • [32] Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: A systematic review and meta-analysis
    Wu, Qibin
    Zhao, Xia
    Yang, Chong
    Yuan, Yinglin
    Yang, Hongji
    Fu, Qiang
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 211
  • [33] Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
    Xie, Qingqing
    Zhang, Pengfei
    Wang, Yuanyuan
    Mei, Wuxuan
    Zeng, Changchun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
    Huang, Jin-Tao
    Zhong, Bin-Yan
    Jiang, Nan
    Li, Wan-Ci
    Zhang, Shuai
    Yin, Yu
    Yang, Jun
    Shen, Jian
    Wang, Wan-Sheng
    Zhu, Xiao-Li
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 1217 - 1228
  • [35] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Chen, Kang
    Wei, Wei
    Liu, Lei
    Deng, Zhu-Jian
    Li, Le
    Liang, Xiu-Mei
    Guo, Ping-Ping
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Gong, Wen-Feng
    Huang, Shan
    Yuan, Wei-Ping
    Ma, Liang
    Xiang, Bang-De
    Li, Le-Qun
    Zhong, Jian-Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074
  • [36] Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
    Sun, Liwei
    Xu, Xuelong
    Meng, Fanguang
    Liu, Qian
    Wang, Hankang
    Li, Xiaodong
    Li, Guijie
    Chen, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
    Houssiau, Helene
    Seront, Emmanuel
    CANCERS, 2022, 14 (07)
  • [38] Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
    Brown, Zachary J.
    Gregory, Stephanie
    Hewitt, D. Brock
    Iacono, Stephen
    Choe, Jennie
    Labiner, Hanna E.
    Pawlik, Timothy M.
    SURGICAL ONCOLOGY-OXFORD, 2022, 42
  • [39] Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Zhao, Mei
    Chen, Shanwen
    Li, Conggui
    Du, Yingying
    Li, Ping
    CANCERS, 2023, 15 (03)
  • [40] Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
    Guardascione, Michela
    Toffoli, Giuseppe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 19